Background
==========

The number of cases, the crude and age-standardized incidence, mortality rates and the prevalence proportions estimated by the Italian Association of Cancer Registries (AIRTUM) presently providing the epidemiological indicators for the major cancers used in ICD-O-3.1 \[[@B1]-[@B3]\]. By 2012, the breast cancer incidence in women (age 25±over 85 years) was about 29%; trends for stomach and colorectal cancer were about 5% and 14% for both genders (age 35/45±over 85 years); the lung cancer incidence rates was about 15% in men (age 45±over 85 years) and 6% in women (age 40±over 85) in 2009 \[[@B4],[@B5]\]. From 2011 onwards the tendency changed: the female rates (20 per 100,000) increased much more rapidly than the male rates \[[@B6]\].

Aim of this study is to examine the relationships among the incidence of genera-cancer-associated risk factors and routine laboratory in cancer patients through CRF.

Materials and Methods
=====================

The CRF database has been developed by a dedicated working group using Delphi process. It contain anonymous records on patient characteristics (gender, age, alcohol and smoking history, height, body weight, performance status measured using the Eastern Cooperative Oncology Group-ECOG PS, chronic comorbidities weighted by the Charlson Comorbidity Index-CCI, type and stage of tumor) (Figure [1](#F1){ref-type="fig"}) \[[@B7]-[@B9]\] and one set of biomarker laboratory data identified in several variables (Table [1](#T1){ref-type="table"}) \[[@B10],[@B11]\].
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###### 

Multivariate Analyses of cancer type, comorbidity score and biomarkers laboratory

  ----------------------------------------------------------------------
  Comorbidity        Breast\     Colon-rectum\   Stomach\    Lung\
                     p           p               p           p
  ------------------ ----------- --------------- ----------- -----------
  HCT_cod            0.105       0.708           0.387       0.078

  Hb_cod             0.035       0.775           0.466       0.351

  RBC_cod            0.564       0.343           0.194       0.448

  WBC_cod            0.292       0.172           0.930       0.583

  PLT_cod            0.167       0.535           0.401       0.332

                                                             

  **CCI_SCORE ≥4**   **0.495**   **0.029**       **0.092**   **0.381**
  ----------------------------------------------------------------------

cancer type: breast, colon-rectum, stomach and lung; biomarkers laboratory: HCT, Hb, RBC, WBC, PLT;

comorbidity: CCI_SCORE **≥4**.

Results
=======

Between 2012 and 2014, 1373 cancer patients were enrolled at three Italian Oncological Institutions after informed consent. Among these patients, 36% were men and 64% were women (mean age 71±45 years) (Figure [2](#F2){ref-type="fig"}) and breast was the most frequent type cancer (43%) followed by lung (29%), colon-rectum (18%) and stomach (9%). 72% (n=85) of the lung, 67% (n=24) of the stomach, 33% (n=25) of the colon-rectum, 4% (n=7) of the breast cancer patients had comorbidities weighted with 3 point and above (Age Unadjusted Charlson-Comorbidity-Index≥4; HR=6.38; 99% CI \[3.07,13.24\]) \[[@B12],[@B13]\] (Figure [3](#F3){ref-type="fig"}). Multivariate analysis determined that comorbidity was highly associated with cancer type, stage and ECOG PS (p=0.01) (Figure [4](#F4){ref-type="fig"}). Evaluation between cardiovascular disease, risk of bleeding, deep-vein thrombosis and colon-rectum cancer stage (p=0.01), breast (p=0.03), lung (p=0.01) compared into comorbidities (Figure [5](#F5){ref-type="fig"}). The other tested variables: Hgb level, neutrophil and platelet counthad had the strongest relationship with breast, lung cancer stage (p=0.02), stomach (p=0.002) and colon-rectum (p=0.1) \[[@B14],[@B15]\].

![CCI and their respective point scores.](1745-6215-16-S1-P23-2){#F2}

![CCI and their respective point scores.](1745-6215-16-S1-P23-3){#F3}

![Multivariate Analysis and the comorbidities of CCI with IBM SPSS Italian version 21 statistical software.](1745-6215-16-S1-P23-4){#F4}

![Multivariate Analysis and the comorbidities of CCI with IBM SPSS Italian version 21 statistical software.](1745-6215-16-S1-P23-5){#F5}

Conclusions
===========

The appropriateness of results could be useful to better describe the role of CRF and biomarkers recorded in patient charts as well as the other variables could allow nurses to identify patients at risk for shorter survival time following hospitalization \[[@B16],[@B17]\].
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